Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, and Pirfenidone) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,125	169 Pages	Allied Market Research	January, 2022	ALMR17046152

Best Price Guarantee
Price	from $4,125
Length	169 Pages
Publisher	Allied Market Research
Published Date	January, 2022
SKU	ALMR17046152

Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, and Pirfenidone) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2030

The global idiopathic pulmonary fibrosis market was valued at $3,126.08 million in 2020, and is projected to reach $6,169.37 million by 2030, registering a CAGR of 7.0% from 2021 to 2030.

Idiopathic pulmonary fibrosis is a chronic lung disease or a condition in which the tissues in lungs become thick and stiff over time. As a result of thickening of lung tissues, brain, and other organs are unable receive optimum oxygen. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.

The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. Many affected individuals also experience a loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen.

The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug, distribution channel and region. According to type of drug, the market is divided into pirfenidone and nintedanib. On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online providers. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA).

The major companies profiled in the report include AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Mission Therapeutics., GNI Group Ltd, Galapagos NV, Biogen, Bristol-Myers Squibb Company., and Shiongi Co Ltd.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global idiopathic pulmonary fibrosis market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the products and end users of idiopathic pulmonary fibrosis used across the globe.
Key market players and their strategies have been analysed to understand the competitive outlook of the market.

By Drug Type

Pirfenidone
Nintedanib

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Providers

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY Players

AstraZeneca PLC
Bristol-Myers Squibb Company
Boehringer Ingelheim
GNI Group Ltd
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Shiongi co Ltd
Mission Therapeutics
Biogen, Inc
Galapagos NV
FibroGen, Inc

List of Company Profiles

AstraZeneca Plc
Biogen Inc.
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen, Inc.
Mission Therapeutics.
GNI Group Ltd
Galapagos NV
Biogen
Bristol-Myers Squibb Company.
Shiongi Co Ltd

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key benefits for stakeholders; 1.3.Key market segments; 1.3.1.List of key players profiled in the report; 1.4.Research methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.1.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Top player positioning, 2020; 3.4.Porter’s five forces analysis; 3.4.1.Bargaining power of suppliers; 3.4.2.Bargaining power of buyers; 3.4.3.Threat of new entrants; 3.4.4.Threat of substitutes; 3.4.5.Intensity of competitive rivalry; 3.5.MARKET DYNAMICS; 3.5.1.Drivers; 3.5.1.1.Increase in incidences of cancer across the globe; 3.5.1.2.Surge in global geriatric population; 3.5.1.3.Increase in cigarette smoking; 3.5.2.Restraint; 3.5.2.1.Lack of awareness & Proper treatment.; 3.5.3.Opportunities; 3.5.3.1.Increase in number of pipeline drugs; 3.5.3.2.Growth opportunities in emerging markets; 3.5.4.Impact analyses; 3.6.COVID-19 impact analysis on market; 3.7.Pipeline analyses
CHAPTER 4:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE: 4.1.Overview; 4.1.1.Market size and forecast; 4.2.Pirfenidone; 4.2.1.Key market trends, growth factors, and opportunities; 4.2.2.Market size and forecast; 4.2.3.Market analysis, by country; 4.3.Nintedanib; 4.3.1.Key market trends, growth factors, and opportunities; 4.3.2.Market size and forecast; 4.3.3.Market analysis, by country
CHAPTER 5:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL: 5.1.Overview; 5.1.1.Market size and forecast, by distribution channel; 5.2.Hospital- pharmacies; 5.2.1.Market size and forecast, by region; 5.2.2.Market analysis, by country; 5.3.Retail pharmacy; 5.3.1.Market size and forecast, by region; 5.3.2.Market analysis, by country; 5.4.Online Pharmacy; 5.4.1.Market size and forecast, by region; 5.4.2.Market analysis, by country
CHAPTER 6:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION: 6.1.Overview; 6.1.1.Market size and forecast; 6.2.North America; 6.2.1.Key market trends, growth factors, and opportunities; 6.2.2.North America market size and forecast, by country; 6.2.3.North America market size and forecast, by drug type; 6.2.4.North America market size and forecast, by distribution channel; 6.2.4.1.U.S.; 6.2.4.2.U.S. market size and forecast, by drug type; 6.2.4.3.U.S. market size and forecast, by distribution channel; 6.2.4.4.Canada; 6.2.4.5.Canada market size and forecast, by drug type; 6.2.4.6.Canada market size and forecast, by distribution channel; 6.2.4.7.Mexico; 6.2.4.8.Mexico market size and forecast, by drug type; 6.2.4.9.Mexico market size and forecast, by distribution channel; 6.3.Europe; 6.3.1.Key market trends, growth factors, and opportunities; 6.3.2.Europe market size and forecast, by country; 6.3.3.Europe market size and forecast, by drug type; 6.3.4.Europe market size and forecast, by distribution channel; 6.3.4.1.Germany.; 6.3.4.2.Germany market size and forecast, by drug type; 6.3.4.3.Germany market size and forecast, by distribution channel; 6.3.4.4.France; 6.3.4.5.France market size and forecast, by drug type; 6.3.4.6.France market size and forecast, by distribution channel; 6.3.4.7.UK; 6.3.4.8.UK market size and forecast, by drug type; 6.3.4.9.UK market size and forecast, by distribution channel; 6.3.4.10.Italy; 6.3.4.11.Italy market size and forecast, by drug type; 6.3.4.12.Italy market size and forecast, by distribution channel; 6.3.4.13.Spain; 6.3.4.14.Spain market size and forecast, by drug type; 6.3.4.15.Spain market size and forecast, by distribution channel; 6.3.4.16.Rest of Europe; 6.3.4.17.Rest of Europe market size and forecast, by drug type; 6.3.4.18.Rest of Europe market size and forecast, by distribution channel; 6.4.Asia-Pacific; 6.4.1.Key market trends, growth factors, and opportunities; 6.4.2.Asia-Pacific market size and forecast, by country; 6.4.3.Asia-Pacific market size and forecast, by drug type; 6.4.4.Asia-Pacific market size and forecast, by distribution channel; 6.4.4.1.Japan; 6.4.4.2.Japan market size and forecast, by drug type; 6.4.4.3.Japan market size and forecast, by distribution channel; 6.4.4.4.China; 6.4.4.5.China market size and forecast, by drug type; 6.4.4.6.China market size and forecast, by distribution channel; 6.4.4.7.India; 6.4.4.8.India market size and forecast, by drug type; 6.4.4.9.India market size and forecast, by distribution channel; 6.4.4.10.Australia; 6.4.4.11.Australia market size and forecast, by drug type; 6.4.4.12.Australia market size and forecast, by distribution channel; 6.4.4.13.South Korea; 6.4.4.14.South Korea market size and forecast, by drug type; 6.4.4.15.South Korea market size and forecast, by distribution channel; 6.4.4.16.Rest of Asia-Pacific; 6.4.4.17.Rest of Asia-Pacific market size and forecast, by drug type; 6.4.4.18.Rest of Asia-Pacific market size and forecast, by distribution channel; 6.5.LAMEA; 6.5.1.Key market trends, growth factors, and opportunities; 6.5.2.LAMEA market size and forecast, by country; 6.5.3.LAMEA market size and forecast, by drug type; 6.5.4.LAMEA market size and forecast, by application; 6.5.4.1.Brazil; 6.5.4.2.Brazil market size and forecast, by drug type; 6.5.4.3.Brazil market size and forecast, by distribution channel; 6.5.4.4.Saudi Arabia; 6.5.4.5.Saudi Arabia market size and forecast, by drug type; 6.5.4.6.Saudi Arabia market size and forecast, by distribution channel; 6.5.4.7.South Africa; 6.5.4.8.South Africa market size and forecast, by drug type; 6.5.4.9.South Africa market size and forecast, by distribution channel; 6.5.4.10.Rest of LAMEA; 6.5.4.11.Rest of LAMEA market size and forecast, by drug type; 6.5.4.12.Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 7:COMPANY PROFILES: 7.1.AstraZeneca Plc.; 7.1.1.Company overview; 7.1.2.Company snapshot; 7.1.3.Operating business segments; 7.1.4.Product Portfolio; 7.1.5.Business performance; 7.1.6.Key strategic moves and developments; 7.2.BOEHRINGER INGELHEIM INTERNATIONAL GMBH; 7.2.1.Company overview; 7.2.2.Company snapshot; 7.2.3.Operating business segments; 7.2.4.Product portfolio; 7.2.5.Business performance; 7.3.Bristol-Myers Squibb Company; 7.3.1.Company overview; 7.3.2.Company snapshot; 7.3.3.Operating business segments; 7.3.4.Product portfolio; 7.3.5.Business performance; 7.4.Biogen,Inc; 7.4.1.Company overview; 7.4.2.Company snapshot; 7.4.3.Operating business segments; 7.4.4.Product portfolio; 7.4.5.Business performance; 7.5.FibroGen, Inc; 7.5.1.Company overview; 7.5.2.Company snapshot; 7.5.3.Operating business segments; 7.5.4.Product portfolio; 7.5.5.Business performance; 7.6.F. Hoffmann-La Roche AG; 7.6.1.Company overview; 7.6.2.Company snapshot; 7.6.3.Operating business segments; 7.6.4.Product portfolio; 7.6.5.Business performance; 7.6.6.Key strategic moves and developments; 7.7.GNI Group Ltd.; 7.7.1.Company overview; 7.7.2.Company snapshot; 7.7.3.Operating business segments; 7.7.4.Product portfolio; 7.7.5.Business performance; 7.8.Galapagos NV.; 7.8.1.Company overview; 7.8.2.Company snapshot; 7.8.3.Operating business segments; 7.8.4.Product portfolio; 7.8.5.Business performance; 7.9.Mission Therapeutics; 7.9.1.Company overview; 7.9.2.Company snapshot; 7.9.3.Operating business segments; 7.9.4.Product portfolio; 7.10.Shionogi & Co Ltd; 7.10.1.Company overview; 7.10.2.Company snapshot; 7.10.3.Operating business segments; 7.10.4.Product portfolio; 7.10.5.Business performance
LIST OF TABLES: TABLE 01.PRODUCT PIPELINE ANALYSIS (PHASE II & III); TABLE 02.GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION); TABLE 03.PIRFENIDONE MARKET, BY REGION, 2020–2030 ($MILLION); TABLE 04.NINTEDANIB MARKET, BY REGION, 2020–2030($MILLION); TABLE 05.GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 06.HOSPITAL- PHARMACIES MARKET, BY REGION, 2020–2030 ($MILLION); TABLE 07.IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION); TABLE 08.IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION); TABLE 09.IDIOPATHIC PULMONARY FIBROSIS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION); TABLE 10.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION); TABLE 11.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION); TABLE 12.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION); TABLE 13.U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 14.U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 15.CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 16.CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 17.MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 18.MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 19.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION); TABLE 20.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION); TABLE 21.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION); TABLE 22.GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 23.GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 24.FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 25.FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 26.UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 27.UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 28.ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 29.ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 30.SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 31.SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 32.REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 33.REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 34.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION); TABLE 35.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION); TABLE 36.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION); TABLE 37.JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 38.JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 39.CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 40.CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 41.INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 42.INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 43.AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 44.AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 45.SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 46.SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 47.REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 48.REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 49.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION); TABLE 50.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION); TABLE 51.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION); TABLE 52.BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 53.BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 54.SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 55.SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 56.SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 57.SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 58.REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION); TABLE 59.REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION); TABLE 60.ASTRAZENECA: COMPANY SNAPSHOT; TABLE 61.ASTRAZENECA: OPERATING SEGMENTS; TABLE 62.ASTRAZENECA: PRODUCT PORTFOLIO; TABLE 63.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT; TABLE 64.BOEHRINGER INGELHEIM: OPERATING SEGMENTS; TABLE 65.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO; TABLE 66.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT; TABLE 67.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS; TABLE 68.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO; TABLE 69.BIOGEN: COMPANY SNAPSHOT; TABLE 70.BIOGEN: OPERATING SEGMENTS; TABLE 71.BIOGEN: PRODUCT PORTFOLIO; TABLE 72.FIBROGEN: COMPANY SNAPSHOT; TABLE 73.FIBROGEN: OPERATING SEGMENTS; TABLE 74.LILLY: PRODUCT PORTFOLIO; TABLE 75.ROCHE: COMPANY SNAPSHOT; TABLE 76.ROCHE: OPERATING SEGMENTS; TABLE 77.ROCHE: PRODUCT PORTFOLIO; TABLE 78.GNI: COMPANY SNAPSHOT; TABLE 79.GNI: PRODUCT SEGMENTS; TABLE 80.GNI: PRODUCT PORTFOLIO; TABLE 81.GALAPAGOS: COMPANY SNAPSHOT; TABLE 82.GALAPAGOS: OPERATING SEGMENTS; TABLE 83.GALAPAGOS: PRODUCT PORTFOLIO; TABLE 84.MISSION: COMPANY SNAPSHOT; TABLE 85.MISSION: OPERATING SEGMENTS; TABLE 86.MISSION: PRODUCT PORTFOLIO; TABLE 87.SHIONOGI: COMPANY SNAPSHOT; TABLE 88.SHIONOGI: OPERATING SEGMENTS; TABLE 89.SHIONOGI: PRODUCT TYPE PORTFOLIO
LIST OF FIGURES: FIGURE 01.IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION; FIGURE 02.TOP INVESTMENT POCKETS; FIGURE 03.TOP PLAYER POSITIONING, 2020; FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 05.HIGH BARGAINING POWER OF BUYERS; FIGURE 06.HIGH THREAT OF NEW ENTRANTS; FIGURE 07.MODERATE THREAT OF SUBSTITUTES; FIGURE 08.MODERATR INTENSITY OF COMPETITIVE RIVALRY; FIGURE 09.IMPACT ANALYSES; FIGURE 10.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR PIRFENIDONE, BY COUNTRY, 2020 & 2030 (%); FIGURE 11.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR NINTEDANIB, BY COUNTRY, 2020 & 2030 (%); FIGURE 12.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR HOSPITAL- PHARMACIES, BY COUNTRY, 2020 & 2030 (%); FIGURE 13.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%); FIGURE 14.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PROVIDER, BY COUNTRY, 2020 & 2030 (%); FIGURE 15.ASTRAZENECA: REVENUE, 2018–2020($MILLION); FIGURE 16.ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020(%); FIGURE 17.ASTRAZENECA: REVENUE SHARE, BY REGION, 2020(%); FIGURE 18.BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION); FIGURE 19.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENTS, 2020 (%); FIGURE 20.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 21.REVENUE, 2018–2020 ($MILLION); FIGURE 22.BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 23.BIOGEN: NET SALES, 2018–2020 ($MILLION); FIGURE 24.BIOGEN: REVENUE SHARE BY REGION, 2020(%); FIGURE 25.FIBROGEN: NET SALES, 2018–2020 ($MILLION); FIGURE 26.FIBROGEN: REVENUE SHARE, BY REGION, 2020(%); FIGURE 27.ROCHE: NET SALES, 2018–2020 ($MILLION); FIGURE 28.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 29.ROCHE: REVENUE SHARE, BY REGION, 2020(%); FIGURE 30.GNI: NET SALES, 2018–2020 ($MILLION); FIGURE 31.GALAPAGOS: NET SALES, 2018–2020 ($MILLION); FIGURE 32.SHIONOGI: REVENUE, 2018–2020 ($MILLION)